the Netherlands: 503B, and what it actually costs here
the Netherlands: 503B, and what it actually costs here, which sounds obvious until you try to state the evidence for it.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.
best — the order this archive was captured in
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
[removed by moderator]
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
503A or 503B — do you know which?
compounded is not generic, there is no equivalence claim
the price difference is mostly the intake, not the vial